摘要
目的探讨恩替卡韦抗病毒治疗对慢性乙型肝炎患者外周血B淋巴细胞亚群的影响。方法慢性乙型肝炎患者60例,随机分为对照组、治疗组各30例。对照组仅给予常规治疗,治疗组另外给予恩替卡韦0.5 mg/d,口服,疗程48周。检测治疗前后患者外周血CD5+B细胞(CD5+,CD19+)及传统B细胞(CD5-,CD19+)百分率。结果对照组治疗前后外周血CD5+B淋巴细胞百分率无明显变化,治疗组治疗后较治疗前明显下降,且明显低于对照组(P<0.05)。结论恩替卡韦治疗对于慢性乙型肝炎患者体液免疫失衡有改善作用。
Purpose To analysis the effect of Entecavir on peripheral blood B lymphocyte subsets in chronic hepatitis B patients. Methods 60 patients were randomly divided into treatment group and con- trol group. Patients in treatment group were received Enteeavir O. 5 mg/d for 48 weeks. The percentages of CD5 ＋ B cells（ CD5 ＋ ,CD19 ＋ ） and traditional B cells（ CDS-,CD19 ＋ ） were measured using immu- nofluorescence double-staining and flow cytometry. Results Compared with control group, treatment of Entecavir can reduce the percentages of peripheral blood CD5 ＋ B lymphocytes statistically. Conclu- sion Entecavir seemed to present corrective proper for the humoral immune imbalance of chronic hepatitis B patients.
出处
《中国生化药物杂志》
CAS
CSCD
北大核心
2012年第6期888-889,共2页
Chinese Journal of Biochemical Pharmaceutics
基金
辽宁省教育厅资助项目(L2010329)
